Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by WatchLearnEarnon Mar 23, 2018 12:03am

66 Views

Post# 27767387

RE:C45 Passes Second Reading

Yeah, you said that. --

donwil8 wrote: It shouldn't concern Kalytera, but C45 does have some short term effect on market sentiment.

While it shouldn't concern Kalytera, in terms of market sentiment, C45 does have a short term effect. https://globalnews.ca/news/4100321/marijuana-legalization-bill-c45-passes-senate/

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload